%A Chen Luojun, Li Na, Tian Jingyuan, Song Qibin, Yu Jinming %T Progress of circulating tumor cells in clinical application %0 Journal Article %D 2018 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2018.09.009 %P 552-555 %V 45 %N 8 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10516.shtml} %8 2018-09-08 %X Circulating tumor cells (CTCs) are cancerous cells that shed from the primary tumor or metastases into the bloodstream. The currently clinical applicability of CTCs approved by the US Food and Drug Administration (FDA) is that CTCs can be prognostic biomarker for patients with metastatic breast cancer, prostate cancer and colorectal cancer. CTCs also have great potential in the prognosis assessment of other metastatic or localized tumors, as well as early screening of tumors, analysis of molecular profiling, guiding treatment decisions, and monitoring of treatment response. Currently, various studies are being carried out to further explore the clinical application of CTCs, and provide new strategies and new prospects for individualized and precise treatment of cancer patients.